ClinicalTrials.gg
CompletedNCT04473469Updated Jun 3, 2024Results posted

Previously Implanted Pudendal Nerve Stimulation

An interventional study of Medtronic Interstim II Model 3058 Neurostimulator in Urinary Retention and Underactive Bladder, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by University of Michigan · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study seeks to examine the response of the bladder to different pudendal nerve stimulation frequencies, by studying patients who have been previously-implanted with pudendal nerve neurostimulators.

Read the detailed description

The pudendal nerve goes to the urethra, anus, and other areas of the pelvic floor. Electrical stimulation of this nerve can help with bladder, bowel, and sexual problems, and pelvic pain. Researchers do not fully understand how the nerve helps with these functions or how the anatomy is different between people. Successful stimulation of the pudendal nerve may help improve medical care for future patients with bladder problems, pelvic pain, bowel problems, and/or sexual problems.

02

Conditions studied

  • Urinary Retention
  • Underactive Bladder

Keywords

  • Pudendal nerve mapping
  • Nerve stimulation
03

In context

Urinary Retention

241 studies on the registry are indexed under Urinary Retention; 44 are open to participants now.

This study's enrollment of 5 is below the median of 90 across 187 interventional studies indexed under Urinary Retention.

Browse Urinary Retention studies →

Lead sponsor

University of Michigan is the lead sponsor of 1,506 studies on the registry; 192 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 133 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously received an implanted neurostimulator at the pudendal nerve
  • Adult (18 or older), capable of providing own and communicating clearly with the research team
  • Capable of speaking, reading, and understanding English, as all study questionnaires are standardized assessments only available in English.
  • Capable of attending the experimental session

Exclusion criteria

Exclusion Criteria:

  • Pregnant or planning to become pregnant during study. If a woman of child- bearing potential wishes to participate in this study, they will be pre-screened with a test to detect pregnancy
  • Currently has a urinary tract infection (UTI)
  • Currently has or tested positive in the last 14 days for COVID-19, or is symptomatic for COVID-19
  • Unwilling to allow de-identified data to be stored for future use or shared with other researchers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Cystometrogram

    The bladder will be filled to different volumes and electrical stimulation will be applied to the pudendal nerve via the implanted neurostimulator.

    Device: Medtronic Interstim II Model 3058 Neurostimulator

Interventions

  • DeviceMedtronic Interstim II Model 3058 Neurostimulator

    Patients will undergo stimulation of the pudendal nerve. All stimulation parameters used will be within the normal hard-coded limits of the implantable pulse generator (IPG).

06

What researchers measure

Primary outcomes

  1. Evoked Bladder Contractions of at Least 20 Centimeters of Water (cmH2O) During Cystometrogram

    The results reflects the number of participants who experienced an evoked bladder contraction of at least 20 centimeters of water during stimulation of the pudendal nerve. Bladder contractions were evoked by applying nerve stimulation to the pudendal nerve through testing of the participant's implanted stimulator.

    Time frame: Visit 1, approximately 1 week after consent

Secondary outcomes

  1. Selective Stimulation of Pudendal Nerve Branches

    Selective stimulation of pudendal nerve branches for external urethral sphincter closure determined by comparing sensor recordings from distal pudendal nerve branches. The intention was to measure the effect of selective PNS, configured for selective external urethral sphincter stimulation on ULPP, but this selective stimulation for this nerve bundle, as described in the protocol, proved to not be feasible within the experimental sessions. Thus, no data was gathered.

    Time frame: 2 hours

  2. Measurement of Effect of Selective Pudendal Nerve Stimulation (PNS) on Urethral Leak Point Pressure (ULPP)

    Measurement of effect of selective PNS on ULPP using PNS configured for external urethral sphincter selectivity. The intention was to measure the effect of selective PNS, configured for selective external urethral sphincter stimulation on ULPP, but this selective stimulation for this nerve bundle, as described in the protocol, proved to not be feasible within the experimental sessions. Thus, no data was gathered.

    Time frame: 2 hours

07

Results

Posted Jun 3, 2024

Participant flow

Participant flow — Overall Study
MilestoneCystometrogram
Started5
Completed5
Not completed0

Outcome measures

PrimaryEvoked Bladder Contractions of at Least 20 Centimeters of Water (cmH2O) During Cystometrogram

The results reflects the number of participants who experienced an evoked bladder contraction of at least 20 centimeters of water during stimulation of the pudendal nerve. Bladder contractions were evoked by applying nerve stimulation to the pudendal nerve through testing of the participant's implanted stimulator.

Time frame:
Visit 1, approximately 1 week after consent
Reported as:
Count of participants · Participants
Evoked Bladder Contractions of at Least 20 Centimeters of Water (cmH2O) During Cystometrogram
ParticipantsCystometrogram
Evoked Bladder Contractions of at Least 20 Centimeters of Water (cmH2O) During Cystometrogram1
SecondarySelective Stimulation of Pudendal Nerve Branches

Selective stimulation of pudendal nerve branches for external urethral sphincter closure determined by comparing sensor recordings from distal pudendal nerve branches. The intention was to measure the effect of selective PNS, configured for selective external urethral sphincter stimulation on ULPP, but this selective stimulation for this nerve bundle, as described in the protocol, proved to not be feasible within the experimental sessions. Thus, no data was gathered.

Time frame:
2 hours

No measurements were reported for this outcome.

SecondaryMeasurement of Effect of Selective Pudendal Nerve Stimulation (PNS) on Urethral Leak Point Pressure (ULPP)

Measurement of effect of selective PNS on ULPP using PNS configured for external urethral sphincter selectivity. The intention was to measure the effect of selective PNS, configured for selective external urethral sphincter stimulation on ULPP, but this selective stimulation for this nerve bundle, as described in the protocol, proved to not be feasible within the experimental sessions. Thus, no data was gathered.

Time frame:
2 hours

No measurements were reported for this outcome.

Adverse events

Collected over 2 years, 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cystometrogram0/5 (0%)0/5 (0%)0/5 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cystometrogram
Mean58.00 ± 14.68
Sex: Female, Male
Sex: Female, Male(Participants)Cystometrogram
Female3
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cystometrogram
Hispanic or Latino0
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cystometrogram
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White4
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Cystometrogram
United States5
08

Study locations

1 site
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All de-identified IPD collected during the trial will be available.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Will be available twelve months following publication of study findings, or earlier.

Access criteria: Anyone who wishes to access the data.

Data sharing details ↗ · sparc.science

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04473469
Responsible party
Timothy Bruns (Associate Professor of Biomedical Engineering, Medical School, University of Michigan) — Principal investigator
First posted
Jul 16, 2020
Start date
Jan 19, 2021
Primary completion
May 2, 2023
Completion
May 2, 2023
Results posted
Jun 3, 2024
Last update
Jun 3, 2024

Study contacts

Tim Bruns, Ph.D.
principal investigator · University of Michigan
Priyanka Gupta, M.D.
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion